2018
Chapter 17 Managing a Child With OCD Who Is Treatment Refractory
Bloch M. Chapter 17 Managing a Child With OCD Who Is Treatment Refractory. 2018, 329-356. DOI: 10.1016/b978-0-12-811427-8.00017-4.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment-refractory obsessive-compulsive disorderCognitive behavioral therapyFirst-line treatmentOCD symptomsPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEffective first-line treatmentSelective serotonin reuptake inhibitorsIntensive treatment programSerotonin reuptake inhibitorsGlutamate-modulating agentsMajority of childrenTreatment programAntipsychotic augmentationReuptake inhibitorsTreatment refractoryPharmacological treatmentAvailable treatmentsChildrenSubstantial proportionPharmacotherapyTreatmentTherapySymptoms
2015
Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch MH, Storch EA. Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 251-262. PMID: 25791142, PMCID: PMC4460245, DOI: 10.1016/j.jaac.2015.01.011.Peer-Reviewed Original ResearchConceptsTreatment-refractory obsessive-compulsive disorderPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment-Refractory ObsessivePharmacological treatment optionsSide effect profileSerotonin reuptake inhibitorsTreatment of adultsGlutamate-modulating agentsLittle evidence-based dataEvidence of efficacyEvidence-based dataPediatric OCD patientsOCD symptomsAntipsychotic augmentationSSRI dosagesPediatric patientsReuptake inhibitorsEffect profilePediatric populationTreatment optionsPractice guidelinesEffective treatment
2011
Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment
Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacology & Therapeutics 2011, 132: 314-332. PMID: 21963369, PMCID: PMC3205262, DOI: 10.1016/j.pharmthera.2011.09.006.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment-refractory OCDGlutamate-modulating agentsSmall clinical trialsNew treatment strategiesCompulsive disorderExcitatory neurotransmitter glutamatePathophysiology of OCDGlutamate abnormalitiesGlutamate dysregulationMonoaminergic neurotransmissionCurrent therapiesClinical trialsDopaminergic neurotransmissionTreatment strategiesCognitive-behavioral psychotherapyTherapeutic benefitAnimal modelsNeurotransmitter glutamateNeurochemical investigationsPathophysiologyNew therapeuticsDisordersRecent evidenceMedications